- Home
- PRFX vs CYCC Comparison
PRFX vs CYCC Comparison
Compare PRFX & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- CYCC
- Stock Information
- Founded
- PRFX 2007
- CYCC 1992
- Country
- PRFX Israel
- CYCC United States
- Employees
- PRFX N/A
- CYCC N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- CYCC Health Care
- Exchange
- PRFX Nasdaq
- CYCC Nasdaq
- Market Cap
- PRFX 3.0M
- CYCC 3.6M
- IPO Year
- PRFX 2020
- CYCC N/A
- Fundamental
- Price
- PRFX $3.16
- CYCC $0.34
- Analyst Decision
- PRFX Hold
- CYCC Strong Buy
- Analyst Count
- PRFX 1
- CYCC 1
- Target Price
- PRFX N/A
- CYCC $11.00
- AVG Volume (30 Days)
- PRFX 3.2M
- CYCC 404.4K
- Earning Date
- PRFX 01-01-0001
- CYCC 03-18-2025
- Dividend Yield
- PRFX N/A
- CYCC N/A
- EPS Growth
- PRFX N/A
- CYCC N/A
- EPS
- PRFX N/A
- CYCC N/A
- Revenue
- PRFX N/A
- CYCC $74,000.00
- Revenue This Year
- PRFX N/A
- CYCC N/A
- Revenue Next Year
- PRFX N/A
- CYCC $88.68
- P/E Ratio
- PRFX N/A
- CYCC N/A
- Revenue Growth
- PRFX N/A
- CYCC N/A
- 52 Week Low
- PRFX $0.43
- CYCC $0.30
- 52 Week High
- PRFX $16.63
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- PRFX 49.34
- CYCC 46.57
- Support Level
- PRFX $3.22
- CYCC $0.32
- Resistance Level
- PRFX $5.47
- CYCC $0.38
- Average True Range (ATR)
- PRFX 0.34
- CYCC 0.02
- MACD
- PRFX 0.04
- CYCC 0.00
- Stochastic Oscillator
- PRFX 15.97
- CYCC 50.00
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.